Read Our Latest Issue Researchers are developing molecular switches that can inactivate transplanted genes, paving the way for safer gene therapies. First up--better treatments for cancer Humans don't molt," R.J. Kirk tells me. Kirk is a billionaire geek who runs his offices out of West Palm Beach, Fla., a balmy land of pelicans and tangled mangroves. He built his fortune on conventional medications that can be taken as a pill, and I had phoned to talk about his newest endeavors in biotech. I wasn't expecting to hear about bugs. But the molting process, in which a growing insect builds a new exoskeleton to replace an old one that no longer fits, turns out to have some very important properties that can be adapted to make gene therapy, still a largely experimental procedure, safer. This is a preview. Make a selection below to access this issue.Already have access? . Having trouble accessing this article? Please visit our page for more information Discover world-changing science. Explore our digital archive back to 1845, including articles by more than 150 Nobel Prize winners. Follow us Scientific american arabic (c) 2021 Scientific American, a Division of Springer Nature America, Inc. All Rights Reserved. Support our award-winning coverage of advances in science & technology. Already a subscriber? Subscribers get more award-winning coverage of advances in science & technology.